LMA: IPO breathes life into Singapore's bioscience ambitions

An unusual healthcare IPO emerges out of Singapore.

Credit Suisse First Boston and DBS have begun pre-marketing a roughly $150 million IPO for medical devices company LMA Laryngeal Mask Airways. The deal is unusual because it has all the hallmarks of a Nasdaq IPO, but its founders have chosen to list in Singapore instead.

The company currently derives just under 60% of its sales from the US. Were it to list on Nasdaq, there would be a host of other medical services companies against which to benchmark its products, which are used during surgical procedures for anesthesia and airways support in place of simple face masks and endotracheal tubes.

However it chose...

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222